Presentations by Program

Search by Program

Evaluation of the Pharmacokinetics/pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane (DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains

John O'Donnell, Angela Tanudra, April Chen, Dan Hines, Ruben Tommasi, Alita Miller, and Thomas Durand-Reville (Microbe, 2021)

ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative Clinical Isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, and Alita Miller (Microbe, 2021)

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo

Ruben Tommasi, Henry Heine, George Drusano, Jason Cummings, Richard Slayden, Thomas Durand-Reville, John O’Donnell, and Alita Miller (Microbe, 2021)

ETX0462 Inhibits Penicillin-binding Protein 3 of Pseudomonas aeruginosa and Escherichia coli

Adam B. Shapiro, Sarah M. McLeod, Samir H. Moussa and Alita A. Miller (Microbe, 2021)

The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR Pseudomonas aeruginosa

Thomas Durand-Reville, Mark Sylvester, Janelle Comita, Frank Wu, Xiaoyun Wu, Jing Zhang, Jan Romero, Satenig Guler, Camilo Velez-Vega, Adam Shapiro, Nicole Carter, April Chen, Ramkumar Iyer, Samir Moussa, Sarah McLeod, Alita Miller, John O’Donnell and Ruben Tommasi (Microbe, 2021)